Introduction
In the past few years, treatment of PAH has undergone an extraordinary evolution, which has led to the current approval by regulatory agencies of seven targeted PAH drugs with different routes of administration. The approval of additional drugs is expected in the near future. Modern drug therapy leads to a significant improvement in patients' symptomatic status and a slower rate of clinical deterioration. In addition, a meta-analysis performed on 23 randomized controlled trials (RCTs) in PAH patients (published prior to October 2008) reports a 43% decrease in mortality and a 61% reduction in hospitalizations in patients treated with specific drug therapies vs. patients randomized to placebo [4] . These results, achieved after an average treatment period of 14.3 weeks, support the efficacy of the currently approved PAH treatments. Despite this finding, PAH remains a chronic disease without a cure. In addition, the medical and interventional treatments for more advanced cases are still invasive (e.g. continuous parenteral prostanoid therapy) and prone to significant side effects [1, 2] .
The therapy of PAH patients cannot be considered as a mere prescription of drugs but is characterized by a complex interdisciplinary strategy which includes the evaluation of severity, supportive and general measures, the assessment of vasoreactivity, the estimation of efficacy, and combination of different drugs plus interventions (e.g. atrial septostomy, transplantation). In any of these steps, the knowledge and experience of the responsible physicians are critical to optimize the available resources [1, 2] .
Comment:
In light of the high costs of targeted PAH therapies, the consideration of cost efficacy is of relevance. However, when treating patients with a life-threatening disease, medical necessities must always be paramount.
In this context, it is crucial to ensure a proper diagnostic work-up and classification, and to prescribe targeted PAH therapies within the approved indication and meet the requirements of each individual patient. It is the responsibility of PH expert centers to ensure this.

General measures
Psychosomatic or psychological as well as social work support are important for patients with PAH as is the case in all chronic diseases. Encouraging patients and their family members to join patients support groups (in Germany "pulmonale hypertonie e.V.
[phev]") can have positive effects on coping, confidence, and outlook [1, 2] .
Although patients should be encouraged to be active within symptom limits, excessive physical activity that leads to distressing symptoms (e.g., severe breathlessness, exertional dizziness, chest pain, syncope, etc.) should be avoided. On the other hand, there Table 1 Recommendations for general measures [1, 2] .
Statement
Class of recommendation
Level of evidence
It is recommended to avoid pregnancy in patients with PAH is growing evidence for the value of supervised physical training programs in improving exercise performance [5, 6] . Physically deconditioned patients may therefore undertake supervised exercise rehabilitation. This should however only take place in facilities that are specially trained in PAH, and this approach requires further scientific exploration [1, 2] . Patients with PAH should avoid pregnancy. Appropriate consultation and reliable contraception is necessary whereby pharmacological interactions with PAH drugs that may affect the efficacy of hormonal contraceptives must be pointed out.
Travelling to altitudes above 1,500-2,000 m without supplemental O 2 should be avoided. During air travel, the known physiological effects of hypoxia suggest that in-flight O 2 administration should be considered for patients in WHO functional class III and IV and those with arterial blood O 2 pressure consistently below 8 kPa (60 mmHg). A flow rate of 2 L/min will raise inspired O 2 pressure to values seen at sea level [1, 2] (see comment *).
Regular immunizations against influenza and pneumococcal infections are recommended [1, 2] .
Elective surgery is expected to have an increased risk in patients with PAH. It is not clear as to which form of anaesthesia is preferable but epidural is probably better tolerated than general anaesthesia [1, 2] .
Comment:
The [9] . Further international prospective studies will be required in order to make appropriate recommendations.
Supportive therapy
Oral anticoagulants
Despite insufficient available data, oral anticoagulation is recommended in PAH patients unless there are contraindications. Evidence in favour of oral anticoagulation is confined to patients with IPAH, HPAH, and PAH due to anorexigens; it is generally retrospective and based on single center experience [1, 2] . Hence, a class IIa recommendation is given for oral anticoagulation in IPAH, heritable PAH, and PAH due to anorexigens, and a class IIb recommendation is given for patients with APAH ( Table 2) . The recommended target INR is 2.0-3.0. (Special recommendations for patients with Eisenmenger's syndrome and portopulmonary hypertension are listed in Tables 7 and 9 ).
Diuretics
Although there are no randomized controlled trials of diuretics in PAH, clinical experience shows clear symptomatic benefit in fluid-overloaded patients treated with this therapy. Therefore, diuretics are used according to the clinical situation. Since there is no data for the superiority or inferiority of individual substances, the choice and dose of diuretic therapy may be left to the PAH physician. The addition of aldosterone antagonists should also be considered [1, 2] .
Oxygen
The guidance with regard to long-term oxygen therapy in patients with PAH is mainly based on evidence in patients with COPD: When arterial blood O 2 pressure is consistently less than 8 kPa (60 mmHg) patients are advised to take O 2 to achieve an arterial blood O 2 pressure of >8 kPa for at least 15 h/day. Ambulatory O 2 may be considered when there is evidence of symptomatic benefit and correctable desaturation on exercise [1, 2] . Since there are no randomized data to suggest that long-term O 2 therapy is beneficial in patients with PAH, the decision for O 2 therapy has to be made on an individual basis.
Treatment of arrhythmias
The ECS/ERS guidelines include only a brief comment about the use of digoxin for the treatment of atrial tachyarrhythmias to slow ventricular rate. This, however, does not adequately meet the requirements of many patients (see comment).
Comment:
Diuretic [11, 12] . Therefore, appropriate replacement therapy may be helpful -similar as reported for patients with left heart failure. However, the available data for patients with pulmonary hypertension should be regarded as preliminary, and further data must be collected, especially with regard to therapeutic consequences.
Targeted PAH drug therapy
Regarding targeted PAH drug therapy, only the most important aspects of individual therapies are described in this manuscript. For detailed information please refer to the European guidelines and to specialized literature [1] [2] [3] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . The recommended use of the available agents is demonstrated in a treatment algorithm in Fig. 1  [1,2] . The grades of recommendation and the levels of evidence for the individual PAH treatments are also shown in Table 3 . Country-specific regulatory approval and labeling for PAH medical treatments are listed in Table 4 .
Comment:
The approval for inhaled treprostinil was given in 2009 by the FDA but denied in 2010 by the EMA. Therefore, this drug is currently only available in the USA.
Calcium channel blockers
Calcium channel blockers (CCB) are recommended only for PAH patients (not for other forms of PH) who demonstrate a favourable response to acute vasodilator testing at the time of right heart catheterization and meet the defined responder criteria (see article on invasive diagnosis of PH in this Supplement). It is increasingly recognized that one a small number of patients with IPAH meet the responder criteria and do well with CCBs [28, 29] . Patients who have not undergone a vasoreactivity study or those with a negative study should not be started on CCBs because of potential severe side effects (e.g. hypotension, syncope, RV failure) [1, 2] . Therefore, treatment with CCBs should only be initiated at centers with comprehensive experience with PAH patients, since this therapy may have fatal consequences if not indicated.
The CCBs that have been predominantly used in reported studies are nifedipine, diltiazem, and amlodipine, with particular emphasis on the first two [28, 29] . The daily doses of these drugs that have shown efficacy in IPAH are relatively high (120-240 mg for nifedipine, 240-720 mg for diltiazem, up to 20 mg for amlodipine). CCBs should be started at a low dose and up-titrated cautiously to the maximum tolerated dose. Limiting factors for dose increase are usually systemic hypotension and lower limb peripheral edema. If a patient does not show an adequate response (defined as being in WHO functional class I or II and marked hemodynamic improvement), additional PAH therapy should be instituted [1, 2] .
Comment:
Although most data is available for nifedipine and diltiazem, most PH centers in Germany predominantly use amlodipine. The initial dose 
Only in responders to acute vasoreactivity tests. Recommendation class I for idiopathic PAH, heritable PAH, and PAH due to anorexigens; IIa for APAH. b Not approved by the EMA. # Since the ERA sitaxentan has been withdrawn from the market, this compound has been removed from the original ESC/ERS table.
Table 4
Country-specific regulatory approval and labeling for PAH-specific drug therapy 
Endothelin receptor antagonists (ERA)
All approved compound belonging to this drug class (bosentan, ambrisentan) are presumed potentially hepatotoxic and can only be prescribed by registered prescribers. Regular controls of aminotransferases (in 4-week intervals) are required. The specified target doses for ERAs apply to adult patients; for children or patients <40 kg body weight, it is referred to the respective summary of product characteristics and the section "special aspects concerning children" (see below).
• Bosentan [16, 18, 22, 25 ] is a dual endothelin-A and -B receptor antagonist and is approved for the treatment of PAH in WHO functional class II and III. The target dose is 125 mg b.i.d. In children, bosentan is approved from the age of 2 years and is also available in a special pharmaceutical form of 32-mg tablets that can be quartered.
• Ambrisentan [21, 30 ] is a selective endothelin-A receptor antagonist and is approved for the treatment of PAH in WHO functional class II and III with a target dose of 5-10 mg once daily.
Comment:
So far only bosentan has been investigated in a randomized controlled study with patients in functional stage II only, and demonstrated significant improvement of hemodynamics as well as a reduced rate of clinical events even though it did not achieve one of the predefined primary endpoints, the improvement of the 6-minute walking distance [22] [21] . Data from a postmarketing surveillance in the US showed no evidence of hepatotoxicity with the use of ambrisentan. Accordingly, the FDA has removed the recommendation to perform monthly transaminase controls in patients with ambrisentan therapy.
Sitaxentan [13, 14] 
Phosphodiesterase type-5 (PDE-5) inhibitors
• Sildenafil [20, 27] is approved for the treatment of PAH in functional class II and III at a dose of 20 mg t.i.d. In children, sildenafil is approved at the age between 1 and 17 years.
• Tadalafil [19] is approved for the same indication as sildenafil.
The target dose for this compound is 40 mg once daily.
Comment:
There is consensus among the German PH experts that the currently approved dose of 20 
Prostanoids
• Inhaled iloprost [24] is approved in Germany for IPAH in WHO functional class III. It is administered via special nebulizers at a dose of 2.5-5 μg, and inhalations have to be performed 6-9 times per day. Intravenous iloprost [32] is not approved in Europe but represents the most widely used intravenous prostanoid in Germany (see comment). Initiation of therapy and continuous dose adjustments should only be carried out in PH expert centers. As with other systemic prostanoids, there is a risk of life-threatening catheter infections and other side effects that typically occur during treatment with prostanoids (including hypotension, flushing, jaw pain and headaches, nausea, diarrhea, etc.).
• Intravenous epoprostenol [15] was recently approved in Germany, but is currently not widely used in this country.
• Treprostinil (inhaled, subcutaneous, intravenous, oral): oral treprostinil and intravenous treprostinil are not approved in Germany. Subcutaneous treprostinil [26] was not approved by the EMA but by the French pharmaceutical regulatory agency. This approval was adopted in Germany. Inhaled treprostinil [33] is approved in the USA but not in Europe. The approval of inhaled treprostinil in Germany is not expected in the near future. 
Comment
Combination therapy
Since there is currently no cure for PAH, and in the majority of patients the treatment goals as defined below cannot be achieved or maintained by the use of monotherapy, a combination of the above compounds has become the standard of care in many PAH centers, although the long-term safety and efficacy have not yet been amply explored. Numerous case series have suggested that various drug combinations appear to be safe and effective. In one series, a step-wise use of combination therapy according to predefined treatment goals was associated with an improved outcome compared with a historical control group [34] . Results of a few randomized controlled trials evaluating combination therapy for PAH have been published, most of which have demonstrated improved treatment results with a combination regimen [27, 33, 35] . The available data on combination therapy are still insufficient and there are many open questions, including the choice of combination agents, the optimal timing (initial combination in naive patients versus sequential combination according to the response to the first drug, when to switch, and when to combine. Therefore, no detailed recommendations can be given at present. When combination therapy is considered, patients should be treated within clinical trials or registries whenever possible [1, 2] .
Comment:
Combination [19, 33] 
as well as the combination study with intravenous epoprostenol and oral sildenafil (PACES study) which was planned exclusively as a combination therapy trial [27]. The latter study was able to demonstrate a survival benefit in patients receiving combination therapy as compared to monotherapy with intravenous epoprostenol. This has led to a paradigm shift in countries with extensive use of epoprostenol (e.g. USA and France). The indication for combination therapy must always be determined on an individual basis. It is currently recommended in patients who do not respond adequately to monotherapy. Due to the complex decision making, safety reasons and pharmacoeconomic considerations, the decision to initiate combination therapy should be reserved for expert centers only.
Balloon atrial septostomy
Balloon atrial septostomy may improve survival in patients with PAH, although there are no data on the value of this procedure in patients who are treated with targeted PAH drugs, and the impact on long-term survival has not been established in randomized controlled trials. Atrial septostomy should be regarded as palliative or bridging procedure to be performed only by centers with experience in this method [1, 2] . It is not indicated in stable patients receiving drug treatment. Its therapeutic window is narrow, since septostomy should also not be performed as emergency procedure in patients with decompensated right heart failure (e.g. right atrial pressure >20 mmHg, arterial O 2 saturation at rest <80% on room air) [1, 2] .
Comment:
In 
Transplantation
Double lung or heart-lung transplantation continues to be an important therapeutic option for suitable patients who do not respond sufficiently to optimized medical therapy. PAH patients with features of a poor prognosis profile despite maximal treatment should be referred for transplant listing well in advance. Patients with PVOD or pulmonary capillary hemangiomatosis should be listed for transplantation at diagnosis. The overall 5-year survival rate following transplantation for PAH is 45-50%, with evidence of continued good quality of life [1, 2] .
Treatment algorithm
An evidence-based treatment algorithm for patients with PAH is provided in Fig. 1 [1,2] . These recommendations do not apply to other forms of PH. The corresponding levels of evidence and grades of recommendation are shown in Table 3 and refer to scientific evidence and not to the approval status ( Table 4 ). The individual drug classes are listed in alphabetic order. Evidence for the individual therapies mainly applies to IPAH and PAH associated with connective tissue disease. Specific details listed below may apply to other forms of PAH.
Comment:
Supervised rehabilitation is listed among supportive therapies. The corresponding evidence was generated in Germany where all applicable patients were treated in a single specialized center [5] . Therefore, the available data does not allow generalization to all rehabilitation facilities.
According to the ESC/ERS guidelines, i.v. epoprostenol is the only recommended treatment for patients in WHO functional class IV.
However, epoprostenol has only recently been approved in Germany, and the current level of experience is low, while other compounds (e.g., iloprost) are more frequently used.
Drug interactions
Significant drug interactions involving the disease-specific therapies for PAH must be taken into account. In accordance with 
Definition of adequate clinical response
The proper assessment of adequate clinical response to medical therapy is essential for therapeutic decisions, particularly with regard to the escalation treatment and the initiation of a combination therapy. According to the ESC/ERS guidelines, recommend the initiation of a sequential combination therapy is recommended if the clinical status of a patient is not satisfactory on monotherapy (see Fig. 1 ; treatment algorithm). However, the judgement of an unsatisfactory treatment effect may be challenging, and the stage-related definition of inadequate response to therapy as suggested in the ESC/ERS guidelines may be helpful (Table 8) . Furthermore, the guidelines recommend regular follow-up visits and specify treatment goals (see article on non-invasive diagnosis in this Supplement).
Comment:
Criteria of adequate clinical response are listed in Table 15 of the original ESC/ERS guidelines (see also Fig. 2 , in the article on "non- [38, 39] . An open-label phase II study demonstrated that the sGC stimulator riociguat led to an improvement of pulmonary hemodynamics and exercise tolerance in patients with PAH and CTEPH [40] . In contrast to other drug classes, TKIs do not have a vasodilating effect but act purely as antiproliferative agents. [44, 45] .
They inhibit the activation of growth factor receptors (receptor tyrosine kinases) which play a crucial role in the pathobiology of PAH [41-43]. Current data of phase II and phase III studies indicate that the TKI imatinib is effective in improving exercise tolerance, pulmonary hemodynamics and right ventricular function in patients with severe PAH and inadequate response to established therapies
Specific PAH populations
PAH associated with congenital cardiac shunts
The complexity of diagnosis and therapy of patients with congenital cardiac shunts render a detailed presentation impossible at this point so that reference is made to the European guidelines [1, 2] . These patients should also be treated in specialized centers. The recommendations are summarized in Table 9 .
Comment:
Defined treatment goals for Eisenmenger's syndrome do not exist. Only bosentan was investigated for the specific indication of Eisenmenger's syndrome (BREATHE-5 study) and showed significant improvements of pulmonary hemodynamics and exercise tolerance without safety concerns [18] . This does not mean that other PAH drugs are less effective or less safe. Positive effects were also described for sildenafil and epoprostenol in small, uncontrolled studies [46] [47] [48] , and for tadalafil in a randomized controlled study [49] . 
PAH associated with connective tissue disease
PAH occurs in 5-15% of patients with systemic sclerosis, 5-10% of patients with mixed connective tissue disease, and 2-5% of patients with systemic lupus erythematosus (SLE) [51, 52] . Diagnosis and therapy of PAH in these patients largely follows the above-mentioned principles for IPAH, however screening is recommended in asymptomatic patients with systemic sclerosis or mixed connective tissue disease (Table 10 ). The significance of additional immunosuppressive or immunomodulatory therapies depends on the underlying disease. For PAH associated with scleroderma, this approach is believed to be without effect and is not recommended, while immunosuppressive treatment in SLE and PAH has been reported to be successful. Patients with PAH associated with mixed connective tissue disease usually show the same response as scleroderma patients but, in individual cases, may also benefit from immunosuppressive therapy.
Comment:
In patients with collagenosis (e.g. SLE, MCTD), the possibility of immunosuppressive therapy should be evaluated within the framework 
PAH associated with portal hypertension
Portopulmonary hypertension (PoPH) is defined as the occurrence of PAH in patients with portal hypertension. The incidence of PoPH in patients with liver cirrhosis is approximately 0.5-1% [1, 2] . The recommendations of the ESC/ERS guidelines are summarized in Table 11 . Echocardiographic screening to rule out right ventricular load should be performed in patients who are evaluated for liver transplantation, since survival after transplantation depends on the presence and extent of PH. There are no data from controlled studies on the treatment of PoPH. The same treatment algorithm as in IPAH is recommended, however, taking co-morbidities into consideration [1, 2] .
Comment:
Smaller case studies indicate the efficacy and safety of PAH drugs for the treatment of PAH associated with portal hypertension, but there are no data from a randomized controlled trial. This does not mean 
PAH associated with HIV infection
Approximately 0.5% of HIV-infected patients develop PAH [58] . In these patients, the diagnostic work-up and treatment strategies are largely based on the above-mentioned recommendations (see Table 12 ). Positive experiences have been reported with bosentan and sildenafil. In some but not all cases, the use of antiretroviral therapy had a positive effect on the course of PAH. Potential interactions between PAH-specific drugs and antiretroviral therapy must be taken into account (see section on drug interactions). This applies especially to the combination of sildenafil with HIV protease inhibitors (see Table 5 ).
Comment:
Smaller case studies indicate the efficacy and safety of targeted PAH drugs -especially bosentan [59, 60] and sildenafil [61, 62] 
Pulmonary veno-occlusive disease (PVOD)
Since PVOD is usually very difficult to diagnose, one of the most important criteria for the potential presence of PVOD is the insufficient response or clinical worsening on targeted PAH treatment. There is still no medical therapy for PVOD and the prognosis is particularly poor, so that patients should be referred to a transplant center as soon as the corresponding tentative diagnosis is established (Table 13 ).
Specific pediatric aspects
The complexity of diagnosis and therapy in different types of PAH and in different age groups constitutes that children with PAH should be treated exclusively at specialized expert centers. The special aspects in children with PAH are considered in the ESC/ERS guidelines only to the extent that they are valid independent of age. The treatment recommendations currently applicable for Table 13 Recommendations for patients with pulmonary veno-occlusive disease [1, 2] .
Statement
Level of evidence
Referral of patients with PVOD to a transplant center for evaluation is indicated as soon the diagnosis is established I C Patients with PVOD should be managed only in centers with extensive experience in PAH due to the risk of lung edema after the initiation of PAH-specific drug therapy IIa C
Table 14
Recommendations for pediatric PAH [1, 2] .
Statement
Level of evidence
The PH diagnostic work-up proposed for adults should also be considered in children IIa C
The PAH therapeutic algorithm proposed for adults should also be considered in children IIa C adults have been largely adopted for the treatment of children with PAH. There is, however, much less available data from randomized controlled studies in children than in adults. Regarding the recommendation to use the same diagnostic and therapeutic algorithms as for adults, there is a class IIA recommendation, and the level of evidence is C (Table 14) .
Comment and specific recommendations for children:
• [63, 64] .
• The ERA bosentan is approved for children, as it has been specifically investigated in children [65] [66] [67] 
Treatment in referral centers for pulmonary hypertension
Due to the complex issues and often difficult treatment decisions, the ESC/ERS guidelines recommend to refer patients with suspected pulmonary hypertension to a specialized center. This is to ensure the correct diagnosis of patients and the prescription of specific PAH drugs that are appropriate to the indication and meet the needs of the individual patients. PH centers are able to carry out the diagnosis and therapy of all or nearly all forms of PH independently and according to guidelines. The requirements listed in the ESC/ERS guidelines are presented in Table 15 .
Comment:
